These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 37531245

  • 21. Disappearance of a chromosomal abnormality in a young patient with polycythemia vera treated with ropeginterferon alfa-2b.
    Hosoda R, Hashimoto Y, Hara K, Maegaki M, Suzuki S, Hosoda Y, Kawamura K.
    Ann Hematol; 2024 Sep; 103(9):3825-3827. PubMed ID: 39052033
    [No Abstract] [Full Text] [Related]

  • 22. Effective Management of Polycythemia Vera With Ropeginterferon Alfa-2b Treatment.
    Suo SS, Fu RF, Qin A, Shao ZH, Bai J, Chen SN, Duan MH, Zhou H, Xu N, Zhang SJ, Zuo XL, Du X, Wang L, Li P, Zhang XH, Wu DX, Li YN, Zhang JJ, Wang W, Shen WH, Zagrijtschuk O, Sato T, Xiao ZJ, Jin J.
    J Hematol; 2024 Apr; 13(1-2):12-22. PubMed ID: 38644985
    [Abstract] [Full Text] [Related]

  • 23. Cepeginterferon alfa-2b in the treatment of chronic myeloproliferative diseases.
    Melikyan AL, Subortseva IN, Gilyazitdinova EA, Koloshejnova TI, Pustovaya EI, Egorova EK, Kovrigina AM, Sudarikov AB, Abdullaev AO, Lomaia EG, Siordiya NT, Zaritskey AY, Savchenko VG.
    Ter Arkh; 2018 Aug 17; 90(7):23-29. PubMed ID: 30701919
    [Abstract] [Full Text] [Related]

  • 24. Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B.
    Huang YW, Hsu CW, Lu SN, Yu ML, Su CW, Su WW, Chien RN, Hsu CS, Hsu SJ, Lai HC, Qin A, Tseng KC, Chen PJ.
    Hepatol Int; 2020 Dec 17; 14(6):997-1008. PubMed ID: 33099752
    [Abstract] [Full Text] [Related]

  • 25. SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia.
    Verstovsek S, Komatsu N, Gill H, Jin J, Lee SE, Hou HA, Sato T, Qin A, Urbanski R, Shih W, Zagrijtschuk O, Zimmerman C, Mesa RA.
    Future Oncol; 2022 Sep 17; 18(27):2999-3009. PubMed ID: 35924546
    [Abstract] [Full Text] [Related]

  • 26. [Interferon therapy for polycythemia vera].
    Edahiro Y.
    Rinsho Ketsueki; 2023 Sep 17; 64(10):1290-1297. PubMed ID: 37914244
    [Abstract] [Full Text] [Related]

  • 27. Ropeginterferon alfa-2b treatment in a young patient with multi-refractory polycythemia vera and double JAK2 gene mutation: a case report.
    Ligia S, Scalzulli E, Carmosino I, Palumbo G, Molinari MC, Poggiali R, Costa A, Bisegna ML, Martelli M, Breccia M.
    Front Oncol; 2023 Sep 17; 13():1338417. PubMed ID: 38264737
    [Abstract] [Full Text] [Related]

  • 28. Mechanism of Action of Ropeginterferon Alfa-2b in Polycythemia Vera Treatment.
    Qin A.
    Clin Ther; 2024 May 17; 46(5):439-440. PubMed ID: 38697872
    [No Abstract] [Full Text] [Related]

  • 29. Change in Polycythemia Vera Treatment: Ropeginterferon Alfa-2b in Light of Current Trials.
    Gisslinger H.
    Turk J Haematol; 2023 Dec 05; 40(4):266-268. PubMed ID: 38050364
    [Abstract] [Full Text] [Related]

  • 30. Novel therapeutic approaches in polycythemia vera.
    Foucar CE, Stein BL.
    Clin Adv Hematol Oncol; 2018 Nov 05; 16(11):750-757. PubMed ID: 30543590
    [Abstract] [Full Text] [Related]

  • 31. An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: An overview of previous and ongoing studies with perspectives on the future.
    Qin A, Urbanski RW, Yu L, Ahmed T, Mascarenhas J.
    Front Oncol; 2023 Nov 05; 13():1109866. PubMed ID: 36776307
    [Abstract] [Full Text] [Related]

  • 32. Novel Therapies in Polycythemia Vera.
    Tremblay D, Mascarenhas J.
    Curr Hematol Malig Rep; 2020 Apr 05; 15(2):133-140. PubMed ID: 32034662
    [Abstract] [Full Text] [Related]

  • 33. [Myeloproliferative neoplasms: recent progresses in therapy].
    Kamiunten A, Shide K, Shimoda K.
    Rinsho Ketsueki; 2018 Apr 05; 59(6):741-746. PubMed ID: 29973454
    [Abstract] [Full Text] [Related]

  • 34. Study Protocol of a Randomized Controlled Clinical Trial to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in COVID-19 Patients with Comorbidities.
    Liu WD, Hou HA, Li KJ, Qin A, Tsai CY, Sheng WH.
    Adv Ther; 2024 Feb 05; 41(2):847-856. PubMed ID: 38010606
    [Abstract] [Full Text] [Related]

  • 35. Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations.
    Marchetti M, Vannucchi AM, Griesshammer M, Harrison C, Koschmieder S, Gisslinger H, Álvarez-Larrán A, De Stefano V, Guglielmelli P, Palandri F, Passamonti F, Barosi G, Silver RT, Hehlmann R, Kiladjian JJ, Barbui T.
    Lancet Haematol; 2022 Apr 05; 9(4):e301-e311. PubMed ID: 35358444
    [Abstract] [Full Text] [Related]

  • 36. Advances in the Treatment of Polycythemia Vera: Trends in Disease Management.
    Arya Y, Syal A, Gupta M, Gaba S.
    Cureus; 2021 Mar 30; 13(3):e14193. PubMed ID: 33936902
    [Abstract] [Full Text] [Related]

  • 37. [Treatment strategies for low-risk polycythemia vera].
    Ota S.
    Rinsho Ketsueki; 2024 Mar 30; 65(8):810-818. PubMed ID: 39231712
    [Abstract] [Full Text] [Related]

  • 38. Real world experience with ropeginterferon alpha-2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa-2a (Pegasys).
    Okikiolu J, Woodley C, Cadman-Davies L, O'Sullivan J, Radia D, Garcia NC, Harrington P, Kordasti S, Asirvatham S, Sriskandarajah P, Saunders J, Saha C, Sanchez I, deLavallade H, McLornan DP, Harrison CN.
    Leuk Res Rep; 2023 Mar 30; 19():100360. PubMed ID: 36590864
    [Abstract] [Full Text] [Related]

  • 39. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J, Jones J, Takeda A, Davidson P, Price A.
    Health Technol Assess; 2006 Aug 30; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [Abstract] [Full Text] [Related]

  • 40. Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study.
    Kiladjian JJ, Zachee P, Hino M, Pane F, Masszi T, Harrison CN, Mesa R, Miller CB, Passamonti F, Durrant S, Griesshammer M, Kirito K, Besses C, Moiraghi B, Rumi E, Rosti V, Blau IW, Francillard N, Dong T, Wroclawska M, Vannucchi AM, Verstovsek S.
    Lancet Haematol; 2020 Mar 30; 7(3):e226-e237. PubMed ID: 31982039
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.